Development of a marker vaccine candidate against classical swine fever based on the live attenuated vaccine C-strain
Development of a marker vaccine candidate against classical swine fever based on the live attenuated vaccine C-strain
复制标题
基于减毒活疫苗 C 株开发针对猪瘟的候选标记疫苗
DOI：
10.1016/j.vetmic.2020.108741
复制
发表时间：
2020-08-01
影响因子：
3.3
通讯作者：
Qiu, Hua-Ji
中科院分区：
文献类型：
--
作者：
Han, Yuying;Xie, Libao;Qiu, Hua-Ji
猪瘟（CSF）是一种高度传染性且具有经济破坏性的疾病。全球范围内针对 CSF 的经典猪瘟病毒 (CSFV) 兔化疫苗 C 株缺乏区分感染动物和已接种动物的血清学能力 (DIVA)。为了开发符合 DIVA 原理的标记 C 菌株，我们生成并评估了突变体 rHCLV-E2F117A、rHCLV-E2G119A 和 rHCLV-E2P122A，这些突变体在 E2 糖蛋白上单克隆抗体 HQ06 识别表位的 F-117、(119)G 或 P-122 处具有单个氨基酸突变 在兔子和猪中。病毒静脉注射证明所有突变体都保留了兔体内C株的表型，包括发烧反应诱导和脾脏中的复制。值得注意的是，与 C 株和其他两种突变体相比，HQ06 识别的表位不与兔体内 rHCLV-E2P122A 诱导的抗体发生反应。接种后 28 天，对猪进行肌内注射 rHCLV-E2P122A 诱导抗 CSFV 中和抗体，但不诱导针对 HQ06 识别表位的抗体。总的来说，我们的数据表明 rHCLV-E2P122A 是一种有前途的 CSF 标记疫苗候选物。
Classical swine fever (CSF) is a highly contagious and economically damaging disease. Classical swine fever virus (CSFV) lapinized vaccine C-strain against CSF worldwide lacks the capacity for the serological differentiation between infected and vaccinated animals (DIVA). To develop a marker C-strain complying with the DIVA principle, we generated and evaluated mutants rHCLV-E2F117A, rHCLV-E2G119A, and rHCLV-E2P122A, which harbor the single amino acid mutation at F-117, (119)G or P-122 of the monoclonal antibody HQ06-recognized epitope on the E2 glycoprotein in rabbits and pigs. Viral intravenous administration demonstrated that all the mutants retain the phenotype of C-strain in rabbits, including fever response induction and replication in the spleen. Notably, the HQ06-recognized epitope did not react with the antibodies induced by rHCLV-E2P122A in rabbits, in contrast with C-strain and other two mutants. Intramuscular administration of rHCLV-E2P122A in pigs induced anti-CSFV neutralizing antibodies but not antibodies against the HQ06-recognized epitope at 28 days post-inoculation. Collectively, our data demonstrate that rHCLV-E2P122A is a promising marker vaccine candidate against CSF.